榴莲视频

Compared with statins alone, was associated with better survival in acute coronary syndrome, a Polish registry showed. (Journal of the American Heart Association)

What does private equity's entry into cardiology mean for existing trends of ? (STAT+)

Systolic blood pressure (BP) tends to creep up in the U.S., according to research highlighted by the American Heart Association.

Investigational RNAi therapy reduced 24-hour mean systolic BP by more than 15 mm Hg in the KARDIA-1 phase II study, Alnylam Pharmaceuticals announced.

Valsartan failed to slow the progression of in the VANISH clinical trial. (JAMA Cardiology)

Research suggests it takes to incur survival and cardiovascular benefits from walking. (Journal of the American College of Cardiology)

Based on bleeding data, apixaban (Eliquis) in chronic kidney disease patients appears to be rather than 5 mg. (Circulation)

Asians in particular had a instead of warfarin for atrial fibrillation, meta-analysis finds. (JACC: Asia)

Boston Scientific said the FDA approved the newest-generation left atrial appendage closure device.

FDA said it granted marketing authorization to the for preventing esophageal injuries during atrial fibrillation ablation procedures.

The snagged FDA clearance for quick machine learning-based evaluation of coronary artery disease, CorVista Health said.

Women taking tended to have modestly more venous thromboembolic events. (BMJ)

Dutch professional athletes showed minimal cardiovascular risk from . (Heart)

Nobel Prize winner , known for studying the effects of nitric oxide on the heart and blood vessels, died at age 86. (New York Times)

The number of cardiovascular deaths is higher than previous estimates. (Lancet Planetary Health)

A low-cost, high-throughput genotyping array was developed for . (Circulation: Genomic and Precision Medicine)

Retailers' low-cost generic programs offered more limited coverage for . (Annals of Internal Medicine)

predicted deaths, cardiovascular and noncardiovascular alike, in a primary prevention cohort. (Mayo Clinic Proceedings)

FDA announced the removal of risk evaluation and mitigation strategies restrictions from (Lotronex), previously in place due to concerns about ischemic colitis and serious complications of constipation.

Comment